Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2499${count})

  • Therapeutic Pipeline Program, 2021
    Evaluation of a Drug that Removes Excess Iron from the Brain as a Treatment for Parkinson’s Disease

    Study Rationale:
    In Parkinson’s disease (PD), the death of cells in brain regions that control movement causes motor symptoms. Brain imaging studies show that iron builds up in these areas, damaging...

  • Therapeutic Pipeline Program, 2021
    Novel Inhibitors of Cell Death for the Treatment of People with Parkinson’s Disease

    Study Rationale: 
    Subcellular structures called mitochondria perform many critical activities for brain cells. They generate enormous amounts of energy and remove the calcium that floods into neurons...

  • Therapeutic Pipeline Program, 2021
    Studies to Assess the Potential of Gold “Nanocrystals” for the Treatment of Parkinson’s Disease

    Study Rationale: 
    CNM-Au8 is a new type of nanomedicine that consists of tiny crystals made of pure gold. The multifaceted surface of these gold nanocrystals provides a platform for metabolic...

  • Biomarkers, 2021
    Measurement of Mitochondrial DNA in Early Stages of Parkinson’s Disease

    Study Rationale:    
    People with a form of idiopathic REM sleep behavior disorder (iRBD) experience nightmares and lash out physically during a stage of sleep when the body's muscles are normally...

  • Therapeutic Pipeline Program, 2021
    Novel Inhibitors of Protein Aggregation as Potential Therapeutics for Parkinson’s Disease

    Study Rationale: 
    The protein alpha-synuclein can aggregate in brain cells, which leads to brain cell death in Parkinson’s disease (PD). We plan to investigate a novel class of drugs — called protein...

  • Therapeutic Pipeline Program, 2021
    Pharmacological Targeting of Inflammation to Modify Disease Progression in Pre-clinical Models of Parkinson’s Disease

    Study Rationale:
    Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by pronounced brain inflammation. Despite being the most common movement disorder to date, no therapy...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.